FibroGen And BlackBerry On The List Of Winners And Losers Of Friday’s US Session

(VIANEWS) – Another day of trading has ended and here’s today‚Äôs list of stocks that have had significant trading activity in the US session.

The three biggest winners today are FibroGen, Catalyst Pharmaceuticals, and Globalstar.

Rank Financial Asset Price Change Updated (EST)
1 FibroGen (FGEN) 0.68 19.32% 2023-12-21 12:12:15
2 Catalyst Pharmaceuticals (CPRX) 15.90 11.19% 2023-12-21 12:11:29
3 Globalstar (GSAT) 1.86 8.77% 2023-12-21 13:01:04
4 DAQO New Energy (DQ) 25.01 7.48% 2023-12-21 12:54:26
5 Carnival Plc (CUK) 17.68 6.99% 2023-12-21 12:19:33
6 Micron Technology (MU) 84.18 6.97% 2023-12-21 12:13:48
7 LendingTree (TREE) 30.69 6.19% 2023-12-21 12:14:59
8 Carnival (CCL) 19.15 5.95% 2023-12-21 12:53:40
9 Moderna (MRNA) 91.10 5.7% 2023-12-21 12:16:44
10 Exact Sciences (EXAS) 71.08 5.62% 2023-12-21 12:11:58

The three biggest losers today are BlackBerry, Zai Lab, and Paychex.

Rank Financial Asset Price Change Updated (EST)
1 BlackBerry (BB) 3.54 -13.78% 2023-12-21 13:00:56
2 Zai Lab (ZLAB) 26.44 -8.31% 2023-12-21 12:52:03
3 Paychex (PAYX) 119.50 -6.53% 2023-12-21 12:50:54
4 Comcast Holdings (CCZ) 54.00 -5.59% 2023-12-21 12:53:42
5 Canaan (CAN) 2.44 -5.05% 2023-12-21 12:15:58
6 Kemper Corporation (KMPR) 47.22 -4.91% 2023-12-21 05:15:05
7 JinkoSolar Holding Company Limited (JKS) 32.37 -4.49% 2023-12-21 03:11:06
8 Imax Corporation (IMAX) 14.90 -4.24% 2023-12-20 23:48:06
9 Brasilagro Brazilian Agric Real Estate Co Sponsored ADR (LND) 5.20 -4.24% 2023-12-21 09:23:06
10 Lehman ABS 3.50 3.50% Adjustable Corp Backed Tr Certs GS Cap I (JBK) 25.15 -3.19% 2023-12-21 01:17:05

Winners today

1. FibroGen (FGEN) – 19.32%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen jumping 19.32% to $0.68 on Friday, after three successive sessions in a row of losses. NASDAQ jumped 1.26% to $14,963.87, following the last session’s downward trend on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.

More news about FibroGen.

2. Catalyst Pharmaceuticals (CPRX) – 11.19%

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

NASDAQ ended the session with Catalyst Pharmaceuticals jumping 11.19% to $15.90 on Friday while NASDAQ jumped 1.26% to $14,963.87.

Earnings Per Share

As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.55.

PE Ratio

Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 28.91. Meaning, the purchaser of the share is investing $28.91 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.06%.

Volume

Today’s last reported volume for Catalyst Pharmaceuticals is 1358180 which is 10.89% above its average volume of 1224730.

Volatility

Catalyst Pharmaceuticals’s last week, last month’s, and last quarter’s current intraday variation average was 0.57%, 0.37%, and 2.19%.

Catalyst Pharmaceuticals’s highest amplitude of average volatility was 2.41% (last week), 2.30% (last month), and 2.19% (last quarter).

Sales Growth

Catalyst Pharmaceuticals’s sales growth is 74.1% for the current quarter and 19.3% for the next.

More news about Catalyst Pharmaceuticals.

3. Globalstar (GSAT) – 8.77%

Globalstar, Inc. provides mobile satellite services worldwide. The company offers duplex two-way voice and data products, including mobile voice and data satellite communications services and equipment for remote business continuity, recreational usage, safety, emergency preparedness and response, and other applications. It also provides one-way or two-way communications and data transmissions using mobile devices, including the SPOT family of products, such as SPOT X, SPOT Gen4, and SPOT Trace that transmit messages and the location of the device; commercial Internet of Things transmission products to track cargo containers and rail cars, as well as to monitor utility meters, and oil and gas assets; small satellite transmitter modules, such as the STX-3, ST-150 and ST100, and chips that enable an integrator's products to access company's network; and engineering and other communication services using MSS and terrestrial spectrum licenses, as well as undertakes installation of gateways and antennas. The company distributes its products through retailers, sales force, and e-commerce website. Globalstar, Inc. serves recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, construction, utilities, and transportation, as well as natural resources, mining, and forestry markets. The company was founded in 1993 and is headquartered in Covington, Louisiana.

NYSE ended the session with Globalstar jumping 8.77% to $1.86 on Friday while NYSE rose 1.1% to $16,715.99.

Earnings Per Share

As for profitability, Globalstar has a trailing twelve months EPS of $-0.01.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.77%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Globalstar’s EBITDA is 14.56.

Volume

Today’s last reported volume for Globalstar is 6073590 which is 38.56% above its average volume of 4383090.

More news about Globalstar.

4. DAQO New Energy (DQ) – 7.48%

Daqo New Energy Corp., together with its subsidiaries, manufactures and sells polysilicon to photovoltaic product manufacturers in the People's Republic of China. Its products are used in ingots, wafers, cells, and modules for solar power solutions. The company was formerly known as Mega Stand International Limited and changed its name to Daqo New Energy Corp. in August 2009. Daqo New Energy Corp. was founded in 2006 and is based in Shanghai, the People's Republic of China.

NYSE ended the session with DAQO New Energy rising 7.48% to $25.01 on Friday, following the last session’s downward trend. NYSE rose 1.1% to $16,715.99, following the last session’s downward trend on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, DAQO New Energy has a trailing twelve months EPS of $8.83.

PE Ratio

DAQO New Energy has a trailing twelve months price to earnings ratio of 2.83. Meaning, the purchaser of the share is investing $2.83 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.37%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, DAQO New Energy’s stock is considered to be oversold (<=20).

More news about DAQO New Energy.

5. Carnival Plc (CUK) – 6.99%

Carnival Corporation & plc engages in the provision of leisure travel services. The company operates a fleet of more than 90 ships visit approximately 700 ports under AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line, Princess Cruises, P&O Cruises (Australia), P&O Cruises (UK), and Seabourn brand names. It also provides port destinations and other services, as well as owns and owns and operates hotels, lodges, glass-domed railcars, and motorcoaches. The company sells its cruises primarily through travel agents, tour operators, vacation planners, and websites. It operates in the United States, Canada, Continental Europe, the United Kingdom, Australia, New Zealand, Asia, and internationally. Carnival Corporation & plc was founded in 1972 and is headquartered in Miami, Florida.

NYSE ended the session with Carnival Plc jumping 6.99% to $17.68 on Friday while NYSE jumped 1.1% to $16,715.99.

Earnings Per Share

As for profitability, Carnival Plc has a trailing twelve months EPS of $-1.29.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.17%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Carnival Plc’s EBITDA is 15.04.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Carnival Plc’s stock is considered to be oversold (<=20).

Yearly Top and Bottom Value

Carnival Plc’s stock is valued at $17.68 at 01:32 EST, higher than its 52-week high of $17.67.

More news about Carnival Plc.

6. Micron Technology (MU) – 6.97%

Micron Technology, Inc. designs, develops, manufactures, and sells memory and storage products worldwide. The company operates through four segments: Compute and Networking Business Unit, Mobile Business Unit, Embedded Business Unit, and Storage Business Unit. It provides memory and storage technologies comprising dynamic random access memory semiconductor devices with low latency that provide high-speed data retrieval; non-volatile and re-writeable semiconductor storage devices; and non-volatile re-writable semiconductor memory devices that provide fast read speeds under the Micron and Crucial brands, as well as through private labels. The company offers memory products for the cloud server, enterprise, client, graphics, networking, industrial, and automotive markets, as well as for smartphone and other mobile-device markets; SSDs and component-level solutions for the enterprise and cloud, client, and consumer storage markets; discrete storage products in component and wafers; and memory and storage products for the automotive, industrial, and consumer markets. It markets its products through its direct sales force, independent sales representatives, distributors, and retailers; and web-based customer direct sales channel, as well as through channel and distribution partners. Micron Technology, Inc. was founded in 1978 and is headquartered in Boise, Idaho.

NASDAQ ended the session with Micron Technology rising 6.97% to $84.18 on Friday, following the last session’s downward trend. NASDAQ jumped 1.26% to $14,963.87, following the last session’s downward trend on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, Micron Technology has a trailing twelve months EPS of $-6.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.41%.

More news about Micron Technology.

7. LendingTree (TREE) – 6.19%

LendingTree, Inc., through its subsidiary, LT Intermediate Company, LLC, operates online consumer platform in the United States. It operates through three segments: Home, Consumer, and Insurance. The Home segment offers purchase mortgage, refinance mortgage, reverse mortgage, and home equity loans; lines of credit; and real estate brokerage services. The Consumer segment provides credit cards; personal, small business, student, and auto loans; deposit accounts; and other credit products, such as credit repair and debt settlement services. The Insurance segment includes information, tools, and access to insurance quote products, including home and automobile, through which consumers are matched with insurance lead aggregators to obtain insurance offers. In addition, the company offers QuoteWizard.com, a marketplace for insurance comparison; ValuePenguin, a personal finance website that offers consumers objective analysis on various financial topics from insurance to credit cards; and Stash, a consumer investing and banking platform that offers a suite of personal investment accounts, traditional and Roth IRAs, custodial investment accounts, and banking services, including checking accounts and debit cards with a Stock-Back rewards program. The company was formerly known as Tree.com, Inc. and changed its name to LendingTree, Inc. in January 2015. LendingTree, Inc. was incorporated in 1996 and is based in Charlotte, North Carolina.

NASDAQ ended the session with LendingTree rising 6.19% to $30.69 on Friday, following the last session’s downward trend. NASDAQ jumped 1.26% to $14,963.87, following the last session’s downward trend on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, LendingTree has a trailing twelve months EPS of $-11.27.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -94.15%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is a negative 86.8% and positive 48% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

LendingTree’s EBITDA is 1.08.

More news about LendingTree.

8. Carnival (CCL) – 5.95%

Carnival Corporation & plc engages in the provision of leisure travel services. The company operates a fleet of more than 90 ships visit approximately 700 ports under AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line, Princess Cruises, P&O Cruises (Australia), P&O Cruises (UK), and Seabourn brand names. It also provides port destinations and other services, as well as owns and owns and operates hotels, lodges, glass-domed railcars, and motorcoaches. The company sells its cruises primarily through travel agents, tour operators, vacation planners, and websites. It operates in the United States, Canada, Continental Europe, the United Kingdom, Australia, New Zealand, Asia, and internationally. Carnival Corporation & plc was founded in 1972 and is headquartered in Miami, Florida.

NYSE ended the session with Carnival jumping 5.95% to $19.15 on Friday while NYSE jumped 1.1% to $16,715.99.

Earnings Per Share

As for profitability, Carnival has a trailing twelve months EPS of $-1.29.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.17%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 59.2%, now sitting on 20.04B for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Carnival’s EBITDA is 23.23.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Carnival’s stock is considered to be oversold (<=20).

Moving Average

Carnival’s worth is way above its 50-day moving average of $13.88 and way above its 200-day moving average of $13.59.

Previous days news about Carnival

  • Carnival (ccl) gears up for Q4 earnings: what's in store?. According to Zacks on Tuesday, 19 December, "Our proven model doesn’t conclusively predict an earnings beat for Carnival this time around. "
  • Unveiling Carnival (ccl) Q4 outlook: wall street estimates for key metrics. According to Zacks on Tuesday, 19 December, "That said, let’s delve into the average estimates of some Carnival metrics that Wall Street analysts commonly model and monitor.", "View all Key Company Metrics for Carnival here>>>Shares of Carnival have experienced a change of +26% in the past month compared to the +5.2% move of the Zacks S&P 500 composite. "
  • Carnival (ccl) reports Q4 loss, tops revenue estimates. According to Zacks on Thursday, 21 December, "While Carnival has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
  • Here's what key metrics tell us about Carnival (ccl) Q4 earnings. According to Zacks on Thursday, 21 December, "Here is how Carnival performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
  • Carnival (ccl) Q4 earnings & revenues top estimates, rise y/y. According to Zacks on Thursday, 21 December, "Carnival Corporation price-consensus-eps-surprise-chart | Carnival Corporation Quote"

More news about Carnival.

9. Moderna (MRNA) – 5.7%

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Moderna rising 5.7% to $91.10 on Friday, following the last session’s downward trend. NASDAQ jumped 1.26% to $14,963.87, following the last session’s downward trend on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, Moderna has a trailing twelve months EPS of $-9.23.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.04%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Moderna’s EBITDA is 2.68.

Volatility

Moderna’s last week, last month’s, and last quarter’s current intraday variation average was 1.26%, 0.78%, and 2.37%.

Moderna’s highest amplitude of average volatility was 1.72% (last week), 1.97% (last month), and 2.37% (last quarter).

Volume

Today’s last reported volume for Moderna is 2890160 which is 36.34% below its average volume of 4540650.

More news about Moderna.

10. Exact Sciences (EXAS) – 5.62%

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

NASDAQ ended the session with Exact Sciences jumping 5.62% to $71.08 on Friday while NASDAQ jumped 1.26% to $14,963.87.

Earnings Per Share

As for profitability, Exact Sciences has a trailing twelve months EPS of $-1.58.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -9.06%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 33.3% and 14.3%, respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Exact Sciences’s stock is considered to be oversold (<=20).

More news about Exact Sciences.

Losers Today

1. BlackBerry (BB) – -13.78%

BlackBerry Limited provides intelligent security software and services to enterprises and governments worldwide. The company operates through three segments: Cybersecurity, IoT, and Licensing and Other. The company offers CylancePROTECT, an endpoint protection platform and mobile threat defense solution; CylanceOPTICS, an endpoint detection and response solution; CylanceGUARD, a managed detection and response solution; CylanceGATEWAY, an AI-empowered zero-trust network access solution; CylancePERSONA, a user and entity behavior analytics solution; BlackBerry unified endpoint management, a central software component for secure communications platform; BlackBerry Dynamics, a development platform and secure container for mobile applications; and BlackBerry Workspaces solutions. It also provides BlackBerry SecuSUITE, a multi-OS voice and text messaging solution; BlackBerry AtHoc and BlackBerry Alert, which are secure and networked critical event management solutions; BlackBerry QNX that offers real-time operating systems, hypervisors, middleware, development tools, and professional services; BlackBerry Certicom, a cryptography and key management product; BlackBerry Radar, an asset monitoring solution; and BlackBerry IVY, an intelligent vehicle data platform. In addition, the company is involved in the patent licensing and legacy service access fees business. The company was formerly known as Research In Motion Limited and changed its name to BlackBerry Limited in July 2013. BlackBerry Limited was incorporated in 1984 and is headquartered in Waterloo, Canada.

NYSE ended the session with BlackBerry sliding 13.78% to $3.54 on Friday while NYSE rose 1.1% to $16,715.99.

Earnings Per Share

As for profitability, BlackBerry has a trailing twelve months EPS of $-0.99.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.13%.

Previous days news about BlackBerry

  • Blackberry (bb) Q3 earnings rise y/y, revenues miss estimates. According to Zacks on Thursday, 21 December, "Recently, BlackBerry announced the appointment of John J. Giamatteo as its new chief executive officer and as a member of its board of directors with immediate effect. ", "For the nine months ended Nov 30, 2023, BlackBerry generated $12 million of net cash in operating activities against $253 million of cash used in the comparable period in fiscal 2023."

More news about BlackBerry.

2. Zai Lab (ZLAB) – -8.31%

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.

NASDAQ ended the session with Zai Lab dropping 8.31% to $26.44 on Friday, following the last session’s downward trend. NASDAQ jumped 1.26% to $14,963.87, following the last session’s downward trend on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, Zai Lab has a trailing twelve months EPS of $-3.1.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -30.29%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Zai Lab’s EBITDA is 8.05.

Yearly Top and Bottom Value

Zai Lab’s stock is valued at $26.44 at 01:32 EST, way under its 52-week high of $49.81 and way higher than its 52-week low of $22.35.

Sales Growth

Zai Lab’s sales growth is 18.9% for the current quarter and 37.1% for the next.

More news about Zai Lab.

3. Paychex (PAYX) – -6.53%

Paychex, Inc. provides integrated human capital management solutions for human resources (HR), payroll, benefits, and insurance services for small to medium-sized businesses in the United States, Europe, and India. It offers payroll processing services; payroll tax administration services; employee payment services; and regulatory compliance services, such as new-hire reporting and garnishment processing. The company also provides HR solutions, including payroll, employer compliance, HR and employee benefits administration, risk management outsourcing, and the on-site availability of a professionally trained HR representative; and retirement services administration, including plan implementation, ongoing compliance with government regulations, employee and employer reporting, participant and employer online access, electronic funds transfer, and other administrative services. In addition, it offers cloud-based HR administration software products for employee benefits management and administration, time and attendance, digital communication solutions, recruiting, and onboarding solutions; plan administration outsourcing and state unemployment insurance services; various business services to small to medium-sized businesses comprising payroll funding and outsourcing services, which include payroll processing, invoicing, and tax preparation; and payment processing services, financial fitness programs, and a small-business loan resource center. Further, the company provides insurance services for property and casualty coverage, such as workers' compensation, business-owner policies, cyber security protection, and commercial auto, as well as health and benefits coverage, including health, dental, vision, and life. It markets and sells its services primarily through its direct sales force. The company was founded in 1971 and is headquartered in Rochester, New York.

NASDAQ ended the session with Paychex sliding 6.53% to $119.50 on Friday, following the last session’s downward trend. NASDAQ rose 1.26% to $14,963.87, following the last session’s downward trend on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, Paychex has a trailing twelve months EPS of $4.41.

PE Ratio

Paychex has a trailing twelve months price to earnings ratio of 27.1. Meaning, the purchaser of the share is investing $27.1 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 47.5%.

Previous days news about Paychex

  • Compared to estimates, paychex (payx) Q2 earnings: A look at key metrics. According to Zacks on Thursday, 21 December, "Here is how Paychex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"

More news about Paychex.

4. Comcast Holdings (CCZ) – -5.59%

NYSE ended the session with Comcast Holdings dropping 5.59% to $54.00 on Friday, following the last session’s downward trend. NYSE rose 1.1% to $16,715.99, following the last session’s downward trend on what was an all-around bullish trend trading session today.

PE Ratio

Comcast Holdings has a trailing twelve months price to earnings ratio of 46.08. Meaning, the purchaser of the share is investing $46.08 for every dollar of annual earnings.

Moving Average

Comcast Holdings’s worth is under its 50-day moving average of $56.67 and below its 200-day moving average of $55.88.

Volatility

Comcast Holdings’s last week, last month’s, and last quarter’s current intraday variation average was 0.72%, 0.32%, and 2.12%.

Comcast Holdings’s highest amplitude of average volatility was 1.27% (last week), 2.40% (last month), and 2.12% (last quarter).

Volume

Today’s last reported volume for Comcast Holdings is 3271 which is 2695.73% above its average volume of 117.

Yearly Top and Bottom Value

Comcast Holdings’s stock is valued at $54.00 at 01:32 EST, way below its 52-week high of $64.86 and higher than its 52-week low of $51.13.

More news about Comcast Holdings.

5. Canaan (CAN) – -5.05%

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.

NASDAQ ended the session with Canaan sliding 5.05% to $2.44 on Friday, after five consecutive sessions in a row of gains. NASDAQ rose 1.26% to $14,963.87, following the last session’s downward trend on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, Canaan has a trailing twelve months EPS of $-0.47.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.23%.

More news about Canaan.

6. Kemper Corporation (KMPR) – -4.91%

Kemper Corporation, a diversified insurance holding company, provides property and casualty, and life and health insurance in the United States. The company operates through three segments: Specialty Property & Casualty Insurance, Preferred Property & Casualty Insurance, and Life & Health Insurance. It provides automobile, homeowners, renters, fire, umbrella, general liability, and other types of property and casualty insurance to individuals; and commercial automobile insurance to businesses. The company also offers life insurance, including permanent and term insurance, as well as supplemental accident and health insurance products; Medicare supplement insurance, fixed hospital indemnity, home health care, specified disease, and accident-only plans to individuals in rural, suburban, and urban areas. It distributes its products through independent agents and brokers. The company was formerly known as Unitrin, Inc. and changed its name to Kemper Corporation in August 2011. Kemper Corporation was founded in 1990 and is headquartered in Chicago, Illinois.

NYSE ended the session with Kemper Corporation falling 4.91% to $47.22 on Friday while NYSE jumped 1.1% to $16,715.99.

Earnings Per Share

As for profitability, Kemper Corporation has a trailing twelve months EPS of $-6.11.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.32%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 11.9%, now sitting on 5.18B for the twelve trailing months.

Yearly Top and Bottom Value

Kemper Corporation’s stock is valued at $47.22 at 01:32 EST, way below its 52-week high of $68.15 and way above its 52-week low of $38.32.

Sales Growth

Kemper Corporation’s sales growth is negative 23.2% for the current quarter and negative 20.7% for the next.

More news about Kemper Corporation.

7. JinkoSolar Holding Company Limited (JKS) – -4.49%

JinkoSolar Holding Co., Ltd., together with its subsidiaries, engages in the design, development, production, and marketing of photovoltaic products. The company offers solar modules, silicon wafers, solar cells, recovered silicon materials, and silicon ingots. It also provides solar system integration services; and develops commercial solar power projects. The company sells its products to distributors, project developers, and system integrators; and utility, commercial, and residential customers under the JinkoSolar brand, as well as on an original equipment manufacturer basis. As of December 31, 2019, it had an integrated annual capacity of 15.0 gigawatt (GW) for silicon wafers, including 11.5 GW for mono wafers; 10.6 GW for solar cells; and 16.0 GW for solar modules. The company has operations in the People's Republic of China, the United States, Japan, Germany, the United Kingdom, Chile, South Africa, India, Mexico, Brazil, the United Arab Emirates, Italy, Spain, France, Belgium, and internationally. JinkoSolar Holding Co., Ltd. was founded in 2006 and is based in Shangrao, the People's Republic of China.

NYSE ended the session with JinkoSolar Holding Company Limited dropping 4.49% to $32.37 on Friday, following the last session’s downward trend. NYSE rose 1.1% to $16,715.99, following the last session’s downward trend on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, JinkoSolar Holding Company Limited has a trailing twelve months EPS of $10.26.

PE Ratio

JinkoSolar Holding Company Limited has a trailing twelve months price to earnings ratio of 3.15. Meaning, the purchaser of the share is investing $3.15 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.23%.

Yearly Top and Bottom Value

JinkoSolar Holding Company Limited’s stock is valued at $32.37 at 01:32 EST, way below its 52-week high of $61.27 and way above its 52-week low of $25.15.

More news about JinkoSolar Holding Company Limited.

8. Imax Corporation (IMAX) – -4.24%

IMAX Corporation, together with its subsidiaries, operates as an entertainment technology company that specializes in digital and film-based motion picture technologies worldwide. It offers cinematic solution comprising proprietary software, theater architecture, intellectual property, and equipment. The company offers Digital Re-Mastering (DMR), a proprietary technology that digitally enhances the image resolution, visual clarity, and sound quality of motion picture films for projection on IMAX screens; IMAX premium theater systems to exhibitor customers through sales, long-term leases, and joint revenue sharing arrangements; film post-production services; and camera and other miscellaneous items rental services, as well as distributes documentary films; and owns and operates IMAX theaters. It also designs, manufactures, installs, sells, and leases IMAX theater projection system equipment; maintains IMAX theater projection system equipment in the IMAX theater network; distributes and licenses original content, virtual reality, IMAX home entertainment, and others; and sells or leases its theater systems to theme parks, private home theaters, tourist destination sites, fairs, and expositions, as well as engages in the after-market sale of projection system parts and 3D glasses. The company markets its theater systems through a direct sales force and marketing staff. It owns or otherwise has rights to trademarks and trade names, which include IMAX, IMAX Dome, IMAX 3D, IMAX 3D Dome, Experience It in IMAX, The IMAX Experience, An IMAX Experience, An IMAX 3D Experience, IMAX DMR, DMR, IMAX nXos, and Films To The Fullest. As of March 31, 2020, the company had a network of 1,616 IMAX theater systems comprising 1,526 commercial multiplexes, 14 commercial destinations, and 76 institutional facilities operating in 81 countries and territories. IMAX Corporation was founded in 1967 and is headquartered in Mississauga, Canada.

NYSE ended the session with Imax Corporation falling 4.24% to $14.90 on Friday, after five successive sessions in a row of losses. NYSE rose 1.1% to $16,715.99, following the last session’s downward trend on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, Imax Corporation has a trailing twelve months EPS of $0.45.

PE Ratio

Imax Corporation has a trailing twelve months price to earnings ratio of 33.11. Meaning, the purchaser of the share is investing $33.11 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.73%.

More news about Imax Corporation.

9. Brasilagro Brazilian Agric Real Estate Co Sponsored ADR (LND) – -4.24%

BrasilAgro – Companhia Brasileira de Propriedades Agrícolas engages in the acquisition, development, exploration, and sale of rural properties suitable for agricultural activities in Brazil. The company operates through six segments: Real Estate, Grains, Sugarcane, Cattle Raising, Cotton, and Other. It is involved in the cultivation of soybean, corn, sorghum, and cotton, as well as sugarcane; and production and sale of beef calves after weaning. The company has 10 farms in 6 Brazilian states and 1 farm in Paraguay with a total area of 215,330 hectares of own lands and 53,735 hectares of leased lands. It also imports and exports agricultural products and inputs; purchases, sells, and/or rents properties, land, buildings, and real estate in rural and/or urban areas; provides real estate brokerage services; and manages third-party assets. The company was incorporated in 2005 and is headquartered in Sao Paulo, Brazil.

NYSE ended the session with Brasilagro Brazilian Agric Real Estate Co Sponsored ADR dropping 4.24% to $5.20 on Friday while NYSE rose 1.1% to $16,715.99.

Earnings Per Share

As for profitability, Brasilagro Brazilian Agric Real Estate Co Sponsored ADR has a trailing twelve months EPS of $0.55.

PE Ratio

Brasilagro Brazilian Agric Real Estate Co Sponsored ADR has a trailing twelve months price to earnings ratio of 9.45. Meaning, the purchaser of the share is investing $9.45 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.34%.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Oct 24, 2023, the estimated forward annual dividend rate is 0.65 and the estimated forward annual dividend yield is 12.59%.

More news about Brasilagro Brazilian Agric Real Estate Co Sponsored ADR.

10. Lehman ABS 3.50 3.50% Adjustable Corp Backed Tr Certs GS Cap I (JBK) – -3.19%

NYSE ended the session with Lehman ABS 3.50 3.50% Adjustable Corp Backed Tr Certs GS Cap I sliding 3.19% to $25.15 on Friday while NYSE rose 1.1% to $16,715.99.

Yearly Top and Bottom Value

Lehman ABS 3.50 3.50% Adjustable Corp Backed Tr Certs GS Cap I’s stock is valued at $25.15 at 01:32 EST, under its 52-week high of $26.11 and above its 52-week low of $23.25.

More news about Lehman ABS 3.50 3.50% Adjustable Corp Backed Tr Certs GS Cap I.

Stay up to date with our winners and losers daily report

Leave a Reply

Your email address will not be published. Required fields are marked *